Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Lacosamide Extended-Release vs. Vimpat in Healthy Fasting Subjects
NCT05788159Phase 1Unknown
- Sponsor
- Overseas Pharmaceuticals
- Start
- Apr 2023
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lacosamide in epilepsy (2 arms), sponsored by Overseas Pharmaceuticals. Primary endpoints: Area under the curve from time zero to last quantifiable concentration at 72 hours, Area under the curve from time zero to infinity at 72 hours and 1 more. Status: unknown.
02
Drugs
lacosamide
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT05788159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05788159.